Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 40 mins


The optimal selection of patients with acute myeloid leukemia (AML) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an area of research that continues to evolve.¹ For patients with favorable-risk AML who achieve first complete remission (CR), there is a clear benefit associated with high-dose cytarabine-based consolidation chemotherapy, whereas patients with high-risk AML with adequate performance status and a suitable donor are candidates for allo-HSCT.

However, while allo-HSCT may be associated with lower rates of relapse in patients with intermediate-risk AML, there is an increased risk of transplant-related mortality. Moreover, at present, there is no agreed optimal treatment strategy for patients classified as intermediate risk; therefore, there is a need to explore the most beneficial therapy for this patient group.¹

Here, we summarize the key points from the ETAL-1 trial by Bornhäuser et al.¹ published in JAMA Oncology, evaluating allo-HSCT versus standard consolidation chemotherapy in patients with intermediate-risk AML.

See th full article in https://aml-hub.com/a/V6